Cadrenal Therapeutics (CVKD) Earnings Date, Estimates & Call Transcripts $11.12 +0.91 (+8.91%) (As of 09/16/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateNov. 14EstimatedActual EPS (Aug. 7) -$2.25 Beat By $16.79 Consensus EPS (Aug. 7) -$19.04 Get Cadrenal Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for CVKD and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCVKD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CVKD Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Cadrenal Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.09)($0.09)($0.09)Q2 20241($0.12)($0.12)($0.12)Q3 20241($0.16)($0.16)($0.16)Q4 20241($0.17)($0.17)($0.17)FY 20244($0.54)($0.54)($0.54)CVKD Earnings Date and InformationCadrenal Therapeutics last released its quarterly earnings data on August 7th, 2024. The reported ($2.25) EPS for the quarter, beating analysts' consensus estimates of ($19.04) by $16.79. Cadrenal Therapeutics has generated ($0.31) earnings per share over the last year (($0.31) diluted earnings per share). Earnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($6.00) to ($4.87) per share. Cadrenal Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off prior year's report dates.Read More Cadrenal Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/14/2024(Estimated)------- 8/7/2024Q2 2024($19.04)($2.25)+$16.79($2.25)--5/9/2024Q1 2024($0.0047)($0.0067)($0.0020)($0.10)-- 3/11/2024Q4 2023($0.0060)($0.0033)+$0.0027($0.05)-- 11/9/2023Q3 2023-($0.0047)($0.0047)($0.07)-- 8/10/2023Q2 2023-($0.0060)($0.0060)($0.09)-- 5/10/2023Q1 2023-($0.0273)($0.0273)($0.34)-- Get the Latest News and Ratings for CVKD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Cadrenal Therapeutics Earnings - Frequently Asked Questions When is Cadrenal Therapeutics's earnings date? Cadrenal Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates. Learn more on CVKD's earnings history. Did Cadrenal Therapeutics beat their earnings estimates last quarter? In the previous quarter, Cadrenal Therapeutics (NASDAQ:CVKD) reported ($2.25) earnings per share (EPS) to beat the analysts' consensus estimate of ($19.04) by $16.79. Learn more on analysts' earnings estimate vs. CVKD's actual earnings. How much profit does Cadrenal Therapeutics generate each year? Cadrenal Therapeutics (NASDAQ:CVKD) has a recorded net income of -$8.36 million. CVKD has generated -$0.31 earnings per share over the last four quarters. What is Cadrenal Therapeutics's EPS forecast for next year? Cadrenal Therapeutics's earnings are expected to grow from ($6.00) per share to ($4.87) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Clene Earnings vTv Therapeutics Earnings Carisma Therapeutics Earnings CalciMedica Earnings Kezar Life Sciences Earnings OncoCyte Earnings Lantern Pharma Earnings Estrella Immunopharma Earnings NextCure Earnings LianBio Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings This page (NASDAQ:CVKD) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredFortune: Nexus Technology has “ignited a gold rush”Business Insider estimates it could grow 8,966% in the near future... And Goldman Sachs says it could grow ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
